Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.11
Previous CloseN/A
Volume25.00K
Average Volume (3M)1.48M
Market Cap
$23.37M
Enterprise Value$10.74M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding60,390,686
10 Day Avg. Volume3,594,428
30 Day Avg. Volume1,479,173
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.94
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$1.50Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTop-line more than doubled since 2021, signaling improving commercial traction for FemVue and related consumables in fertility care. Durable revenue growth supports scaling fixed costs, enables incremental operating leverage over time, and strengthens the case for investment in sales and reimbursement efforts.
Healthy Gross MarginsSustained product-level gross margins near the mid-50s to 60s percent indicate attractive unit economics for core devices and consumables. Strong margins provide a durable buffer to absorb SG&A and R&D, improving the path to profitability as volumes scale and fixed costs are spread.
Regulatory & Manufacturing PositionThe company highlights regulatory approvals, a diversified women’s health portfolio and scalable U.S. manufacturing capability. These structural assets support wider market access, reduce supply bottlenecks, and improve the ability to commercialize new products internationally over the medium term.
Bears Say
Severe Cash BurnPersistent and sizable negative operating and free cash flow imply ongoing external funding needs and constrain strategic flexibility. Large cash burn undermines runway, may force financing at unfavorable terms, and limits ability to autonomously fund commercialization, R&D, or inventory build.
Large Operating LossesExtremely wide negative operating and net margins show the cost base far outpaces current revenue. This structural unprofitability requires sustained revenue ramp or material cost restructuring to achieve durable profitability; until then returns on equity and capital will remain deeply negative.
Financing & Dilution RiskRecent shareholder approvals and amendment authority to issue substantial convertible securities and warrants create meaningful dilution risk and increase reliance on lender-provided capital. That can dilute existing holders, shift governance influence, and signal ongoing dependency on external financing to sustain operations.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.11 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $23.37M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 60,390,686 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
FEMY Stock 12 Month Forecast
Average Price Target
$1.50
▲(105.48% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.01% Insiders
2.62% Mutual Funds
11.06% Other Institutional Investors
81.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---